Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Cash from Operations (2019 - 2025)

Historic Cash from Operations for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to -$8.9 million.

  • Biodesix's Cash from Operations rose 1679.32% to -$8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.1 million, marking a year-over-year increase of 5048.03%. This contributed to the annual value of -$48.6 million for FY2024, which is 11271.97% down from last year.
  • Biodesix's Cash from Operations amounted to -$8.9 million in Q3 2025, which was up 1679.32% from -$6.6 million recorded in Q2 2025.
  • Over the past 5 years, Biodesix's Cash from Operations peaked at $1.1 million during Q2 2021, and registered a low of -$18.6 million during Q2 2024.
  • Its 5-year average for Cash from Operations is -$8.9 million, with a median of -$9.6 million in 2022.
  • Per our database at Business Quant, Biodesix's Cash from Operations skyrocketed by 12533.12% in 2021 and then plummeted by 208196.37% in 2024.
  • Biodesix's Cash from Operations (Quarter) stood at -$10.2 million in 2021, then fell by 17.17% to -$11.9 million in 2022, then fell by 2.8% to -$12.3 million in 2023, then skyrocketed by 66.65% to -$4.1 million in 2024, then tumbled by 116.77% to -$8.9 million in 2025.
  • Its Cash from Operations stands at -$8.9 million for Q3 2025, versus -$6.6 million for Q2 2025 and -$8.6 million for Q1 2025.